| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Halozyme Therapeutics, Inc. (HALO) has 10 insiders with recent SEC Form 4 filings, including 1 buy and 20 sells. HALO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 777.8K | $53.66M | - | |
| Dir | 77.8K | $5.37M | - | |
| Dir | 43.7K | $3.01M | -1,625 | |
| Dir | 36.6K | $2.52M | - | |
| Dir | 23.7K | $1.64M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2018 | Kirk Randal J | 10% Owner | Sell | 572,804 | $17.35 | $9,937,299.04 | -2.2% | |
| Jul 27, 2018 | Kirk Randal J | 10% Owner | Sell | 302,827 | $17.24 | $5,221,414.30 | -1.1% | |
| Jun 29, 2018 | Kirk Randal J | 10% Owner | Sell | 304,321 | $17.04 | $5,186,691.92 | -1.1% | |
| Aug 20, 2015 | Stelzer Laurie | Chief Financial Officer | Buy | 10,000 | $17.24 | $172,384.00 | New | |
| Jun 18, 2015 | Kelley Kenneth J | Director | Sell | 20,000 | $21.00 | $420,000.00 | -9.2% | |
| Mar 5, 2015 | Kelley Kenneth J | Director | Sell | 40,000 | $15.33 | $613,380.00 | -17.0% |